Generate Biomedicines Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Generate Biomedicines stock has a consensus rating of "Strong Buy" and an average price target of $25.4. The average 1-year stock price forecast is 75.29% higher than the current stock price, while the lowest is $22 (+51.83%) and the highest is $30 (+107.04%).

Price Target: $25.4 (+75.29%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$22	$25.4	$25	$30
Change	+51.83%	+75.29%	+72.53%	+107.04%

Analyst Ratings

The average analyst rating for Generate Biomedicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '26	Apr '26	May '26
Strong Buy	3	4	4
Buy	2	2	2
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	5	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Seamus Fernandez Guggenheim	Guggenheim	Buy Maintains $30	Buy	Maintains	$30	+107.04%	Jun 15, 2026
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Maintains $20 → $22	Buy	Maintains	$20 → $22	+51.83%	May 14, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $24	Buy	Reiterates	$24	+65.63%	May 8, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $25	Buy	Reiterates	$25	+72.53%	May 8, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $26	Buy	Maintains	$26	+79.43%	Apr 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

25.89M

from 31.89M

-18.81%

from 31.89M

Revenue Next Year

23.67M

from 25.89M

-8.60%

from 25.89M

EPS This Year

-2.24

from -

EPS Next Year

-2.07

from -2.24

Fiscal Year	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	20.46M	31.89M	25.89M
Revenue Growth	-	55.89%	-18.81%
Operating Income	-196.94M	-235.07M	-275.62M
Net Income	-173.77M	-203.15M	-284.66M
EPS	-	-	-2.24
Free Cash Flow	-	-119.10M	-239.00M
No. Analysts	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	37.2M
Avg	25.9M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	16.6%
Avg	-18.8%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.24
Low	-

EPS Growth

EPS Growth	2027	2028
High	-
Avg	-
Low	-